Aliases & Classifications for Sensory Peripheral Neuropathy

MalaCards integrated aliases for Sensory Peripheral Neuropathy:

Name: Sensory Peripheral Neuropathy 12 14
Sensory Neuropathy 12 72 28 51 69
Hereditary Sensory and Autonomic Neuropathies 41 69
Peripheral Sensory Neuropathy 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2491
ICD9CM 34 356.2
MeSH 41 D009477
NCIt 46 C3501

Summaries for Sensory Peripheral Neuropathy

Disease Ontology : 12 A neuropathy that involves damage to nerves of the peripheral nervous system.

MalaCards based summary : Sensory Peripheral Neuropathy, also known as sensory neuropathy, is related to charcot-marie-tooth disease, x-linked dominant, 1 and charcot-marie-tooth disease, axonal, type 2b, and has symptoms including dysesthesia, neurologic symptoms and sciatica. An important gene associated with Sensory Peripheral Neuropathy is GDAP1 (Ganglioside Induced Differentiation Associated Protein 1), and among its related pathways/superpathways are Brain-Derived Neurotrophic Factor (BDNF) signaling pathway and Guidance Cues and Growth Cone Motility. The drugs Gabapentin and gamma-Aminobutyric acid have been mentioned in the context of this disorder. Affiliated tissues include skin, liver and colon, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Peripheral neuropathy (PN) is damage to or disease affecting nerves, which may impair sensation,... more...

Related Diseases for Sensory Peripheral Neuropathy

Diseases related to Sensory Peripheral Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, x-linked dominant, 1 31.9 GDAP1 GJB1 MPZ
2 charcot-marie-tooth disease, axonal, type 2b 31.4 EGR2 GJB1 MPZ PMP22 SPTLC1
3 neuropathy 27.9 EGR2 GDAP1 GJB1 MFN2 MPZ NGF
4 hereditary sensory and autonomic neuropathy type 1e 12.5
5 neuropathy, hereditary sensory and autonomic, type iia 12.4
6 insensitivity to pain, congenital, with anhidrosis 12.4
7 hereditary motor and sensory neuropathy v 12.4
8 neuropathy, hereditary sensory and autonomic, type vii 12.3
9 neuropathy, hereditary sensory and autonomic, type iii 12.3
10 deafness, x-linked 5 11.4
11 spinocerebellar ataxia, autosomal recessive 16 11.1
12 x-linked hereditary sensory and autonomic neuropathy with deafness 11.1
13 posterior column ataxia with retinitis pigmentosa 11.0
14 cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia 11.0
15 foot drop 10.4 MPZ PMP22
16 sensory neuropathy type 1 10.4 GJB1 SPTLC1
17 charcot-marie-tooth disease, axonal, type 2f 10.3 GJB1 MPZ
18 charcot-marie-tooth disease, type 4b3 10.3 GDAP1 MTMR2
19 charcot-marie-tooth disease, type 4j 10.3 GDAP1 MTMR2
20 charcot-marie-tooth disease, demyelinating, type 1f 10.3 GJB1 MPZ PMP22
21 niemann-pick disease, type a 10.2 MAG MPZ
22 chronic inflammatory demyelinating polyradiculoneuropathy 10.2 MPZ PMP22
23 axonal neuropathy 10.2 GDAP1 MFN2 PMP22
24 cauda equina syndrome 10.2 EGR2 PMP22
25 pelizaeus-merzbacher disease 10.2 MAG MPZ PMP22
26 neuritis 10.2 MAG MPZ PMP22
27 amyotrophic neuralgia 10.1 GJB1 PMP22 PRX
28 charcot-marie-tooth disease, demyelinating, type 4f 10.1 GDAP1 MTMR2 PRX
29 charcot-marie-tooth disease, type 4b2 10.1 GDAP1 MTMR2 PRX
30 charcot-marie-tooth disease, type 4a 10.1 GDAP1 MTMR2 PRX
31 roussy-levy hereditary areflexic dystasia 10.1 GDAP1 MFN2 MPZ PMP22
32 charcot-marie-tooth disease, type 4b1 10.1 GDAP1 MTMR2 PRX
33 polyneuropathy 10.0 GDAP1 MAG MPZ PMP22
34 hereditary neuropathy with liability to pressure palsy 10.0 LITAF MPZ PMP22
35 demyelinating polyneuropathy 10.0 MAG NGF PMP22
36 plexopathy 9.9 NGF PMP22
37 diabetic autonomic neuropathy 9.9 NGF NTF3
38 charcot-marie-tooth neuropathy type 1 9.9 EGR2 GJB1 MPZ PMP22
39 episodic pain syndrome, familial, 1 9.9
40 diabetic neuropathy 9.8 MPZ NGF NTF3 PMP22
41 neuropathy, hereditary motor and sensory, russe type 9.7 EGR2 NDRG1
42 aging 9.7
43 vitamin b12 deficiency 9.7
44 demyelinating disease 9.7
45 charcot-marie-tooth disease, demyelinating, type 1b 9.7 EGR2 GJB1 MPZ MTMR2 PMP22
46 diabetic polyneuropathy 9.7 NGF NTF3
47 hereditary motor and sensory neuropathy, type iic 9.5 GDAP1 GJB1 MFN2 MPZ NDRG1
48 charcot-marie-tooth disease, type 4d 9.3 GDAP1 GJB1 MFN2 NDRG1 NTF3
49 charcot-marie-tooth disease, demyelinating, type 1d 9.1 EGR2 GJB1 MPZ MTMR2 NDRG1 PMP22
50 neuropathy, hereditary, with liability to pressure palsies 9.1 EGR2 GDAP1 GJB1 LITAF MFN2 MPZ

Graphical network of the top 20 diseases related to Sensory Peripheral Neuropathy:



Diseases related to Sensory Peripheral Neuropathy

Symptoms & Phenotypes for Sensory Peripheral Neuropathy

UMLS symptoms related to Sensory Peripheral Neuropathy:


dysesthesia, neurologic symptoms, sciatica, hyperesthesia

GenomeRNAi Phenotypes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

25 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.87 FGD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.87 FGD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 SLC12A6
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.87 NTF3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.87 SLC12A6 FGD4 GJB1 NTF3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 NTF3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.87 FGD4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.87 FGD4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.87 GJB1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.87 FGD4
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.87 NTF3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-163 9.87 GJB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.87 GJB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.87 SLC12A6
15 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.87 NTF3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-205 9.87 FGD4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.87 GJB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.87 SLC12A6
19 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 GJB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.87 SLC12A6
21 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.87 SLC12A6
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 SLC12A6
23 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.87 SLC12A6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.87 GJB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.87 GJB1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.87 FGD4
27 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.87 NTF3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.87 SLC12A6
29 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.87 SLC12A6
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 NTF3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.87 FGD4
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.87 SLC12A6

MGI Mouse Phenotypes related to Sensory Peripheral Neuropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 NTF3 PMP22 PRX SLC12A6 SPTLC1 EGR2
2 growth/size/body region MP:0005378 10.11 EGR2 FLVCR1 GJB1 MFN2 MTMR2 NDRG1
3 homeostasis/metabolism MP:0005376 10.1 EGR2 FLVCR1 GDAP1 GJB1 LITAF MAG
4 nervous system MP:0003631 10.06 EGR2 FGD4 GDAP1 GJB1 LITAF MAG
5 mortality/aging MP:0010768 10 EGR2 FLVCR1 GJB1 MFN2 MPZ MTMR2
6 reproductive system MP:0005389 9.56 PMP22 SLC12A6 SPTLC1 MPZ MTMR2 NTF3
7 vision/eye MP:0005391 9.17 EGR2 GJB1 NDRG1 NGF NTF3 PMP22

Drugs & Therapeutics for Sensory Peripheral Neuropathy

Drugs for Sensory Peripheral Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 172)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
2
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
3
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
4
Hydroxocobalamin Approved Phase 4,Phase 3 13422-51-0 5460373 44475014 11953898
5
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3 68-19-9 44176380
6
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 59-30-3 6037
7
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 58-05-9 143 6006
8
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 3 13422-55-4
9
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2 66-72-8 1050
10
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4,Phase 1,Phase 2 54-47-7 1051
11
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 65-23-6 1054
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
14 Anesthetics Phase 4,Phase 3
15 Anesthetics, Local Phase 4
16 Anti-Anxiety Agents Phase 4
17 Anti-Arrhythmia Agents Phase 4,Phase 3
18 Anticonvulsants Phase 4,Phase 3,Phase 2
19 Antimanic Agents Phase 4
20 Antiparkinson Agents Phase 4
21 calcium channel blockers Phase 4,Phase 3
22 Calcium, Dietary Phase 4,Phase 3,Phase 1,Phase 2
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
24 Diuretics, Potassium Sparing Phase 4
25 Excitatory Amino Acid Antagonists Phase 4,Phase 3
26 Excitatory Amino Acids Phase 4,Phase 3
27 GABA Agents Phase 4
28 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2
30 Sodium Channel Blockers Phase 4
31 Tranquilizing Agents Phase 4,Phase 3,Phase 2
32 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
33 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
34 Vitamin B 12 Phase 4,Phase 3
35 Vitamin B 6 Phase 4,Phase 3,Phase 1,Phase 2
36 Vitamin B Complex Phase 4,Phase 3,Phase 1,Phase 2
37 Vitamins Phase 4,Phase 3,Phase 2,Phase 1
38
Cobalamin Nutraceutical Phase 4,Phase 3 13408-78-1 6438156
39 Folate Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
40 Vitamin B12 Nutraceutical Phase 4,Phase 3
41 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
42
Acetylcarnitine Approved, Investigational Phase 3 3040-38-8 1
43
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
44
Oxaliplatin Approved, Investigational Phase 3,Phase 1,Phase 2 61825-94-3 43805 6857599 5310940 9887054
45
Amitriptyline Approved Phase 3,Phase 2 50-48-6 2160
46
Baclofen Approved Phase 3 1134-47-0 2284
47
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
48
Perphenazine Approved Phase 3,Phase 2 58-39-9 4748
49
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
50
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083

Interventional clinical trials:

(show top 50) (show all 59)

# Name Status NCT ID Phase Drugs
1 Anodyne Therapy in Diabetic Sensory Neuropathy Completed NCT00120341 Phase 4
2 A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
3 Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy Completed NCT00903851 Phase 4 Lidoderm
4 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
5 Clinical Study on Acetyl-L-Carnitine Completed NCT01526564 Phase 3 Acetylcarnitine;Placebo
6 Vitamin E in Preventing Peripheral Neuropathy Caused by Chemotherapy in Patients Receiving Chemotherapy for Cancer Completed NCT00363129 Phase 3
7 XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy Completed NCT00272051 Phase 3 SR57746A
8 Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. Completed NCT00305188 Phase 3 Xaliproden (SR57746A);Placebo;Oxaliplatin;5-Fluorouracil;Leucovorin
9 Oral Glutamine in the Prevention of Oxaliplatin-induced Neurotoxicity Completed NCT01087658 Phase 3 Glutamine;Calcium and Magnesium
10 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
11 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin
12 A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients Completed NCT00659269 Phase 3 Chemotherapy
13 Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer Completed NCT02468739 Phase 3 EC-T or TC plus GM1;EC-T or TC plus placebo
14 Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer Recruiting NCT02289547 Phase 3 Capecitabine
15 PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA Recruiting NCT03006432 Phase 3 Oxaliplatin;5Fluorouracil bolus;5Fluorouracil continu;Docetaxel;Folinic Acid
16 Treatment of Chronic Laryngitis With Amitriptyline Suspended NCT02552225 Phase 2, Phase 3 Amitriptyline
17 Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens Terminated NCT00603577 Phase 3 Placebo;Xaliproden
18 Trial of the Treatment of Chronic Laryngitis With Amitryptiline Terminated NCT02434523 Phase 2, Phase 3 Amitriptyline
19 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
20 Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402) Unknown status NCT02288078 Phase 2 Dexamethasone;Regorafenib;Placebo;Proton pump inhibitor
21 A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy Completed NCT00000842 Phase 2 Nerve Growth Factor, Recombinant Human
22 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 Completed NCT01733407 Phase 1, Phase 2 L-serine;placebo
23 Ascorbic Acid Treatment in CMT1A Trial (AATIC) Completed NCT00271635 Phase 2 Placebo;ascorbic acid
24 Effect of C-Peptide on Diabetic Peripheral Neuropathy Completed NCT00278980 Phase 2 C-peptide
25 Electrical Stimulation Therapy Using the MC5-A Scrambler in Reducing Peripheral Neuropathy Caused by Chemotherapy Completed NCT00952848 Phase 2
26 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
27 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma Completed NCT00287872 Phase 2 bortezomib;thalidomide
28 Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma Completed NCT00153920 Phase 2 bortezomib
29 Cetuximab and Lenalidomide in Head and Neck Completed NCT01133665 Phase 2 Cetuximab and Lenalidomide
30 A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer Completed NCT01619423 Phase 1, Phase 2 PledOx (2 µmol/kg);PledOx (5 µmol/kg);Placebo (0,9% NaCl)
31 The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Recruiting NCT02915263 Phase 2 IGIV-C;0.9% Sodium Chloride
32 Topiramate for Cryptogenic Sensory Peripheral Neuropathy Not yet recruiting NCT02878798 Phase 2 topiramate
33 A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy Terminated NCT00267007 Phase 2 PROCRIT 40,000 IU QW;Placebo
34 Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS) Terminated NCT00231140 Phase 2 Thalidomide (drug)
35 Epoetin Alfa for HIV-Associated Neuropathy Trial Withdrawn NCT00528593 Phase 2 epoetin alfa
36 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
37 Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer Completed NCT02174887 Phase 1 Nab-paclitaxel + Gemcitabine
38 L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer Withdrawn NCT02215083 Phase 1
39 Pathology of Skin, Nerve and Vasculature in the Amputated Limb of Diabetes Unknown status NCT00840164
40 Novel Home Care Device for High-Risk Diabetic Patients Unknown status NCT00500175
41 Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear Completed NCT02451722
42 Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx® Completed NCT00933998
43 Immunotherapy of the Paraneoplastic Syndromes Completed NCT00378326 Tacrolimus
44 OPEN Study: Pain Management Treatment Needs Interviews Completed NCT02972606
45 Microcirculation & ASICs Completed NCT01246180 Diclofenac;Amiloride
46 NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes Completed NCT01707979
47 Characterization of Anti-FGFR3 Antibodies Recruiting NCT02539329
48 Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study Recruiting NCT02555930
49 Tai Chi Easy in Treating Cancer Survivors With Peripheral Sensory Neuropathy Recruiting NCT01980368
50 Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) Recruiting NCT02194010

Search NIH Clinical Center for Sensory Peripheral Neuropathy

Cochrane evidence based reviews: hereditary sensory and autonomic neuropathies

Genetic Tests for Sensory Peripheral Neuropathy

Genetic tests related to Sensory Peripheral Neuropathy:

# Genetic test Affiliating Genes
1 Sensory Neuropathy 28

Anatomical Context for Sensory Peripheral Neuropathy

MalaCards organs/tissues related to Sensory Peripheral Neuropathy:

38
Skin, Liver, Colon, Bone

Publications for Sensory Peripheral Neuropathy

Articles related to Sensory Peripheral Neuropathy:

(show all 15)
# Title Authors Year
1
Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. ( 28447211 )
2017
2
Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy. ( 26015512 )
2015
3
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance). ( 24513692 )
2014
4
Pain, sleep disturbances, and functional limitations in people living with HIV/AIDS-associated distal sensory peripheral neuropathy. ( 25513029 )
2014
5
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. ( 23204130 )
2013
6
Acu/Moxa for distal sensory peripheral neuropathy in HIV: a randomized control pilot study. ( 23582399 )
2013
7
Pain, Sleep Disturbances, and Functional Limitations in People Living with HIV/AIDS-Associated Distal Sensory Peripheral Neuropathy. ( 23887924 )
2013
8
Relation of sensory peripheral neuropathy in SjAPgren syndrome to anti-Ro/SSA. ( 22955477 )
2012
9
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. ( 22843789 )
2012
10
Lack of motor progression in isolated sensory peripheral neuropathy. ( 20724263 )
2010
11
Reversible motor and sensory peripheral neuropathy in a patient following acute carbon monoxide intoxication. ( 15773259 )
2005
12
Screening for distal sensory peripheral neuropathy in HIV-infected persons in research and clinical settings. ( 9855522 )
1998
13
[Chronic hexosaminidase A deficiency associated with pure sensory peripheral neuropathy]. ( 1302293 )
1992
14
Sensory peripheral neuropathy of vitamin B12 deficiency: a primary demyelinating disease? ( 2835439 )
1988
15
Subepidermal vesicular dermatosis and sensory peripheral neuropathy caused by pyridoxine abuse. ( 3011864 )
1986

Variations for Sensory Peripheral Neuropathy

ClinVar genetic disease variations for Sensory Peripheral Neuropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MPZ NM_000530.7(MPZ): c.293G> A (p.Arg98His) single nucleotide variant Pathogenic/Likely pathogenic rs121913589 GRCh37 Chromosome 1, 161276653: 161276653
2 GDAP1 NM_018972.2(GDAP1): c.715C> T (p.Leu239Phe) single nucleotide variant Pathogenic rs104894080 GRCh37 Chromosome 8, 75276240: 75276240

Expression for Sensory Peripheral Neuropathy

Search GEO for disease gene expression data for Sensory Peripheral Neuropathy.

Pathways for Sensory Peripheral Neuropathy

Pathways related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.59 EGR2 NGF NTF3
2 11.4 GDAP1 MAG NGF
3 11.14 GJB1 MPZ PMP22
4
Show member pathways
10.62 MAG NGF NTF3

GO Terms for Sensory Peripheral Neuropathy

Cellular components related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.13 MAG MPZ NDRG1
2 compact myelin GO:0043218 8.62 MAG PMP22

Biological processes related to Sensory Peripheral Neuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron apoptotic process GO:0043524 9.43 MAG NGF NTF3
2 regulation of neuron differentiation GO:0045664 9.37 NGF NTF3
3 peripheral nervous system development GO:0007422 9.32 EGR2 PMP22
4 mitochondrial fusion GO:0008053 9.16 GDAP1 MFN2
5 cell-cell adhesion via plasma-membrane adhesion molecules GO:0098742 8.96 MAG MPZ
6 myelination GO:0042552 8.8 EGR2 MPZ PMP22

Sources for Sensory Peripheral Neuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....